Purchase this article with an account.
Pei-Chang Wu; Low concentration of atropine for the treatment of children myopia: The efficacy of 0.01% verse 0.05% atropine eyedrops. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3405.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
This study aimed to assess the efficacy and safety of atropine 0.01% verse 0.05% eyedrops for the treatment of children with myopia.
In this study, a total of 48 myopic children were randomly divided into 0.01% group and 0.05% group, with 20 and 18 children respectively. The outcome measurements were changes in the spherical equivalent after 1 year and adverse events.
0.05% atropine group had less myopia progression compared with 0.01% atropine group, as measured by SE (-0.49+/-0.27D vs. -0.78+/-0.54D, P=0.039). In the fast myopic progression (greater than -0.5D/yr), there was no significant difference in 0.01% and 0.05% atropine groups (56% vs. 75%, p=0.346). For the PP analysis, 40%(8/20) of subjects in the 0.01% atropine group had slower myopia progression of 0.5 D or less during 1 year, compared with 72%(13/18) in the 0.05% atropine group (p=0.046). For the high frequency of photophobia symptom (often and always), there was no significant difference between 0.01% and 0.05% groups (29% vs. 30%, p=0.540). No serious AEs occurred in both the groups.
Low concentration 0.05% atropine eye drops was more efficacious than 0.01% in controlling myopia. 0.01% atropine had smaller photopic pupil diameter with less persistent photophobia symptom. Both concentration of atropine eye drops were safe for myopic children.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only